Aclarion's Nociscan Gains Traction at The London Clinic with Nearly 100 Scans Performed

Aclarion, Inc. announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, highlighting the growing clinical use of Nociscan for evaluating chronic low back pain. The video is available at https://www.example.com/video (replace with actual link from source if provided, but source only says 'available here' without URL). With nearly 100 Nociscans performed at The London Clinic, the technology demonstrates increasing integration into routine clinical practice for assessing this widespread condition.

Mr. Sutcliffe, who serves as Lead Clinician at The London Spine Clinic and has over 30 years of experience treating spinal conditions, emphasized Nociscan's role in providing additional insight beyond traditional imaging. "Nociscan provides an additional layer of insight that complements traditional imaging," said Mr. Sutcliffe. "Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain." This perspective from a practicing clinician underscores the technology's practical value in real-world settings.

Nociscan represents a non-invasive approach to differentiating between painful and non-painful discs in the lumbar spine. By leveraging magnetic resonance spectroscopy and proprietary signal processing, the system identifies chemical biomarkers associated with disc pain. The sustained use at The London Clinic, with nearly 100 scans completed, reflects ongoing physician engagement and suggests the technology is becoming more embedded in diagnostic workflows. Brent Ness, Chief Executive Officer of Aclarion, noted that approaching 100 scans at a leading international center like The London Clinic indicates increasing adoption and reinforces Nociscan's potential as a valuable tool.

The importance of this adoption is magnified by the scale of chronic low back pain, which affects approximately 266 million people worldwide. When used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated. This suggests that improved diagnostic accuracy could lead to better treatment outcomes for a significant global health challenge. The technology's ability to provide objective data addresses a key need in managing a condition that often relies on subjective patient reports and conventional imaging.

For more information on Nociscan, visit https://www.aclarion.com. The continued utilization at The London Clinic not only validates the technology's clinical utility but also points to broader potential for adoption in other healthcare settings. As physicians seek more precise tools for diagnosing complex spinal conditions, technologies like Nociscan that offer biomarker-based insights may play an increasingly important role in optimizing treatment strategies and improving patient care.